We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Leucocytoclastic vasculitis‐like reaction induced by tocilizumab in a patient with rheumatoid arthritis.
- Authors
Hu, Yu‐Qing; Chen, Xue; Zhang, Jian‐Zhong
- Abstract
It might be likely that the soluble IL-6R and tocilizumab might form immunocomplex and induced similar cutaneous vasculitis.[9] In conclusion, we should be aware of the potential side effects of leucocytoclastic vasculitis induced by tocilizumab. Leucocytoclastic vasculitis-like reaction induced by tocilizumab in a patient with rheumatoid arthritis Tocilizumab is a humanized monoclonal antibody to interleukin-6 (IL-6) receptor which was approved for use in rheumatoid arthritis (RA), juvenile idiopathic arthritis, adult-onset still disease and Crohn disease.[1] Tocilizumab was also used in some autoimmune skin diseases such as morphoea, systemic sclerosis, psoriasis, atopic dermatitis, vitiligo, graftversus-host disease and pyoderma gangrenosum.[2] With the increase of tocilizumab use, several side effects have been reported.[3] We here report a case of annular leucocytoclastic vasculitis induced by tocilizumab.
- Subjects
TOCILIZUMAB; LEUKOCYTOCLASTIC vasculitis; JUVENILE idiopathic arthritis; RHEUMATOID arthritis
- Publication
Dermatologic Therapy, 2022, Vol 35, Issue 12, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.15944